Thomas Poschinger
Overview
Explore the profile of Thomas Poschinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
278
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OBrien N, Mueller J, Broske A, Attig J, Osl F, Crisand C, et al.
MAbs
. 2024 Dec;
17(1):2440578.
PMID: 39686589
T cell bispecific antibodies (TCBs) are a promising new class of therapeutics for relapsed/refractory multiple myeloma. A frequently observed, yet incompletely understood effect of this treatment is the transient reduction...
2.
Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I, et al.
Blood
. 2024 Oct;
145(2):202-219.
PMID: 39476124
Despite several approved therapies, multiple myeloma (MM) remains an incurable disease with high unmet medical need. "Off-the-shelf" T-cell bispecific antibodies (TCBs) targeting B-cell maturation antigen (BCMA) and G protein-coupled receptor...
3.
Mueller J, Dobosz M, OBrien N, Abdoush N, Giusti A, Lechmann M, et al.
Front Immunol
. 2023 Feb;
14:1034032.
PMID: 36845124
Advancing novel immunotherapy strategies requires refined tools in preclinical research to thoroughly assess drug targets, biodistribution, safety, and efficacy. Light sheet fluorescence microscopy (LSFM) offers unprecedented fast volumetric imaging of...
4.
Iurlaro R, Waldhauer I, Planas-Rigol E, Bonfill-Teixidor E, Arias A, Nicolini V, et al.
Mol Cancer Ther
. 2022 Aug;
21(10):1499-1509.
PMID: 35915983
T-cell bispecific antibodies (TCB) are engineered molecules that bind both the T-cell receptor and tumor-specific antigens. Epidermal growth factor receptor variant III (EGFRvIII) mutation is a common event in glioblastoma...
5.
Thamm M, Rosenhain S, Leonardic K, Hofter A, Kiessling F, Osl F, et al.
Front Med (Lausanne)
. 2022 Jul;
9:878966.
PMID: 35872758
Small animal micro computed tomography (μCT) is an important tool in cancer research and is used to quantify liver and lung tumors. A type of cancer that is intensively investigated...
6.
Stoltzfus C, Filipek J, Gern B, Olin B, Leal J, Wu Y, et al.
Cell Rep
. 2020 Apr;
31(3):107523.
PMID: 32320656
Recently developed approaches for highly multiplexed imaging have revealed complex patterns of cellular positioning and cell-cell interactions with important roles in both cellular- and tissue-level physiology. However, tools to quantitatively...
7.
Hage C, Hoves S, Ashoff M, Schandl V, Hort S, Rieder N, et al.
PLoS One
. 2019 Jul;
14(7):e0219517.
PMID: 31291357
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and has a high mortality rate due to limited treatment options. Hence, the response of HCC to different cancer...
8.
Hage C, Hoves S, Strauss L, Bissinger S, Prinz Y, Poschinger T, et al.
Hepatology
. 2019 Apr;
70(4):1280-1297.
PMID: 31002440
Antiangiogenic and cytotoxic effects are considered the principal mechanisms of action of sorafenib, a multitarget kinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC). We report that sorafenib also...
9.
Hage C, Gremse F, Griessinger C, Maurer A, Hoffmann S, Osl F, et al.
J Nucl Med
. 2017 Aug;
59(1):44-50.
PMID: 28848038
Noninvasive imaging technologies are increasingly used in preclinical drug research for the pharmacokinetic analysis of therapeutic compounds in living animals over time. The different preclinical imaging modalities available differ intrinsically...
10.
Suchowski K, Poschinger T, Rehemtulla A, Sturzl M, Scheuer W
Neoplasia
. 2017 Mar;
19(4):310-320.
PMID: 28285180
Aberrant signaling through the AKT kinase mediates oncogenic phenotypes including cell proliferation, survival, and therapeutic resistance. Here, we utilize a bioluminescence reporter for AKT kinase activity (BAR) to noninvasively assess...